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Abstracts / Journal of Nutrition & Intermediary Metabolism 4 (2016) 6e4714a-carotene (p ¼ 0.018) and b-carotene signiﬁcantly increased (p ¼ 0.013).
Older age (p ¼ 0.025), higher pre-intervention uncontrolled eating (p <
0.001) and plasma carotenoids (p ¼ 0.009) predicted weight-loss.
Conclusions: This study provides data which contributes to the charac-
terisation of nutritional biomarkers in obese COPD patients. We have also
demonstrated the efﬁcacy of a weight-loss intervention in improving diet
quality in this population. Future studies are needed to conﬁrm these
ﬁndings, and examine the long-term efﬁcacy of the weight-loss
intervention.
Funding source(s): John Hunter Hospital Charitable Trust Research Grants
Scheme.
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Background/Aims: Improved ﬂow mediated dilatation (FMD) has been
reported in some but not all weight loss studies. Restricting sodium is
known to improve FMD. It is unclear whether weight loss combined with
reduced sodium will have a greater beneﬁt on FMD. This study aimed to
determine the effects of weight loss and reduced sodium intake on FMD.
Methods: Participants were randomly assigned to two groups, in a parallel
design. All participants reduced sodium intake by 50 mmol for one week.
Group 1 (weight loss) then used low sodiummeal replacements for weight
loss, and Group 2 (control, no weight loss) continued their usual diet for 8
weeks. Adherence was assessed using 24 hr urinary sodium excretion.
FMD, blood pressure (BP), and 24 hr urinalysis were measured at baseline
and at completion of each intervention phase.
Results: Twenty-ﬁve participants (14 women; BMI: 34.7 ± 5.9 kg/m2; age:
42 ± 16 y) were enrolled and 23 participants completed the protocol. FMD
(2.3 ± 1.1%, p ¼ 0.04, n ¼ 25) and DBP (-2.7 ± 10mmHg, p ¼ 0.01, n ¼ 25)
improved after the sodium reduction. During the weight loss phase, mean
weight changewas -3.0 ± 3.3 kg Group 1 (n¼ 13) and +1.1 ± 1.2 kg Group 2
(n¼ 10), p¼ 0.02. There were no between group differences in FMD during
the weight loss phase. Urinary sodium decreased in Group 1 (-87 ± 18
mmol/d, p < 0.01) and Group 2 (-95 ± 25 mmol/d, p < 0.01) during sodium
restriction, and remained lower (Group 1: -67 ± 20 mmol/d, p ¼ 0.01;
Group 2: -69 ± 24 mmol/d, p ¼ 0.02) during the weight loss phase.
Conclusions: These results suggest reducing sodium intake improves FMD
but the combination of modest weight loss does not provide additional
beneﬁt.
Funding source(s): Heart Foundation and Government of South Australia.
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Background/Aims: Patients suffering from the inﬂammatory disorder ul-
cerative colitis (UC) have an increased risk of developing colorectal cancer
(CRC). Previously, we demonstrated that Emu Oil (EO) reduced inﬂam-
mation and protected the intestine against UC, NSAID-enteropathy and
chemotherapy-inducedmucositis. We aimed to determine whether orally-
administered EO could reduce the severity of inﬂammation-associated CRC
in mice.
Methods:Mice (n¼ 8 per group) were orally-administered either water or
EO (EO1: 80 mL or EO2: 160 mL), thrice weekly. Mice were injected with
azoxymethane (AOM), followed by 3 cycles each consisting of 7 days
dextran sulphate sodium (DSS) and 14 days drinking water; and culled 3
weeks after the last cycle. Bodyweights, organ data and colonic tumour
numbers were recorded. P < 0.05 was considered signiﬁcant.
Results: During the ﬁrst 2 DSS-weeks, AOM/DSS decreased bodyweightgain compared to normal controls (maximum 23%; p < 0.05). However, in
AOM/DSS mice, EO2 increased bodyweight gain compared to untreated
and EO1-treated mice (maximum 10%; p < 0.05) during the 3rd DSS-week
until cull. Spleen weight was greater in AOM/DSS-treated mice (water: 0.3
± 0.03%; EO1: 0.3 ± 0.05%; EO2: 0.3 ± 0.03% relative to bodyweight)
compared to normal controls (0.2 ± 0.05%; p < 0.05). Thymus weight
decreased only in AOM/DSS control mice, compared to normal controls (p
< 0.05). AOM/DSS resulted in CRC development (water: 10.1 ± 1.7; EO1:
10.3 ± 1.2; EO2: 9.4 ± 1.7 tumour count) compared to normal controls (0 ±
0; p < 0.05).
Conclusions: Despite improved bodyweight, emu oil did not decrease the
number of colonic tumours. Further studies underway include assess-
ments of tumour size, histological morphometry, apoptosis and prolifer-
ation and pro-inﬂammatory cytokines.
Funding source(s): Cancer Council of Western Australia.
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Background/Aims: A high Omega-3 Index is associated with a lower risk
of sudden cardiac death, and dietary ﬁsh oil supplementation has been
shown to improve cardiovascular disease (CVD) risk factors. There is little
research examining CVD risk factor modiﬁcation resulting from change in
the Omega-3 Index due to ﬁsh oil supplementation. We aimed to assess
the effects of 12 weeks ﬁsh oil supplementation on change in Omega-3
Index together with CVD risk factors.
Methods: Fifty overweight men were randomised to receive ﬁsh oil (1728
mg ﬁsh oil containing 1000mg EPA + DHA per day) combined with 200mg
antioxidant (coenzyme Q10), or placebo (2 g olive oil) for 12 weeks.
Anthropometry and biochemical outcomes were measured at baseline, six
and 12 weeks supplementation. Relationships between change in Omega-
3 Index and change in anthropometric and biochemical outcomes were
examined by linear regression.
Results: Forty-eight men completed the trial. Baseline Omega-3 Index was
high in both the ﬁsh oil and placebo groups (7.9 ± 0.4% and 8.1 ± 0.3%,
respectively). Fish oil supplementation resulted in a large and signiﬁcant
increase in Omega-3 Index (D 2.8 ± 0.3%), whereas placebo supplemen-
tation did not (D 0.3 ± 0.2%, p < 0.001). There was no signiﬁcant effect of
change in Omega-3 Index on CVD risk markers (p > 0.05 for all).
Conclusions: In overweight menwith a high baseline Omega-3 Index ﬁsh,
oil supplementation increased the Omega-3 Index but this was not asso-
ciated with improvement in CVD risk markers.
Funding source(s): Blackmores Australia Ltd.
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Background/Aims: Adipokines, such as resistin and adiponectin, may
contribute to increased asthma risk and severity in obese people. We
aimed to examine plasma resistin and resistin:adiponectin ratio in asth-
matics compared to healthy controls, according to asthma severity, BMI
and gender, following weight loss in obese asthmatics.
Methods: In a cross-sectional observational study of asthmatic adults (n ¼
96) and healthy controls (n ¼ 46), plasma resistin and adiponectin were
measured. In a separate intervention study, obese asthmatic adults (n ¼
27) completed a 10-weekweight-loss intervention and plasma resistin and
adiponectin were measured.
